DNX Biopharmaceuticals, Inc. and XL-protein GmbH (XLp) have entered a strategic collaboration for the development and commercialization of novel, long-acting biopharmaceutical products. XLp will contribute its half-life extension platform technology (PASylation) and certain molecules that have completed in vivo efficacy and preclinical studies, and DNX will add its pipeline of molecules for development and commercialization to address a range of unmet needs in immunology, metabolism and ophthalm...